Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04922229 · ClinicalTrials.gov registry record · NA

Comparative Effectiveness in the Management of Irreversible Pulpitis

A NA study, sponsored by University of Alabama at Birmingham.

Not yet
Registry status
NA
Development phase
138
Enrollment target

NCT04922229: Clinical Trial NA study, sponsored by University of Alabama at Birmingham.

NCT04922229 is a NA study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 138 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04922229, a NA study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.

NOT YET RECRUITING
Registry status
NA
Development phase
138 participants
Enrollment target

Study Summary

This project addresses a central question within the practice of dentistry: Is a pulpotomy procedure effective in the treatment of a tooth with symptomatic irreversible pulpitis and normal periapex? In addition, the project seeks to identify clinical and molecular biomarkers that are predictive of the success of pulpotomy.

Primary Outcome

A composite of clinical and radiographic findings and incidence of follow up procedures

Interventions

  • PROCEDURE Pulpotomy
  • PROCEDURE RCT

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2027-06-01
Est. Completion 2031-12-31
Phase NA
University of Alabama at Birmingham

1,160 total trials

What is known before NCT04922229 opens enrollment

NCT04922229 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 2 interventions - of which Pulpotomy is the first listed.

NCT04922229 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04922229 about?

NCT04922229 is a clinical study titled "Comparative Effectiveness in the Management of Irreversible Pulpitis". This project addresses a central question within the practice of dentistry: Is a pulpotomy procedure effective in the treatment of a tooth with symptomatic irreversible pulpitis and normal periapex? In addition, the project seeks to identify clinical and molecular biomarkers that are predictive of t...

What is the current status of trial NCT04922229?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 138 participants. The study started on 2027-06-01. Estimated completion is 2031-12-31.

What interventions are being tested in trial NCT04922229?

The interventions under investigation include: Pulpotomy (PROCEDURE), RCT (PROCEDURE).

Who is sponsoring clinical trial NCT04922229?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04922229's enrollment target sits among peer trials

138 720th of 2000 higher than 1,279 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04402788 · 138 participants · Phase 2

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • NCT04883255 · 138 participants · Early Phase 1

    Cannabis Use, Cognition, and the Endocannabinoid System in HIV

  • NCT05620784 · 138 participants · Phase 3

    Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

  • NCT05832086 · 138 participants · Phase 2

    Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04922229, the US trial registry maintained by the National Library of Medicine. NCT04922229 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.